Raphael Pinto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3656715/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Aminoguanidine and metformin prevent the reduced rate of HDL-mediated cell cholesterol efflux induced by formation of advanced glycation end products. International Journal of Biochemistry and Cell Biology, 2006, 38, 392-403.	1.2	42
2	Advanced glycated albumin isolated from poorly controlled type 1 diabetes mellitus patients alters macrophage gene expression impairing ABCAâ€1â€mediated reverse cholesterol transport. Diabetes/Metabolism Research and Reviews, 2013, 29, 66-76.	1.7	35
3	In Type 2 Diabetes Mellitus Glycated Albumin Alters Macrophage Gene Expression Impairing ABCA1â€Mediated Cholesterol Efflux. Journal of Cellular Physiology, 2015, 230, 1250-1257.	2.0	29
4	ER stress is associated with reduced ABCA-1 protein levels in macrophages treated with advanced glycated albumin – Reversal by a chemical chaperone. International Journal of Biochemistry and Cell Biology, 2012, 44, 1078-1086.	1.2	28
5	Aerobic Exercise Improves Reverse Cholesterol Transport in Cholesteryl Ester Transfer Protein Transgenic Mice. Lipids, 2011, 46, 617-625.	0.7	26
6	Inhibition of Macrophage Oxidative Stress Prevents the Reduction of ABCAâ€1 Transporter Induced by Advanced Glycated Albumin. Lipids, 2012, 47, 443-450.	0.7	22
7	Aerobic exercise training enhances the in vivo cholesterol trafficking from macrophages to the liver independently of changes in the expression of genes involved in lipid flux in macrophages and aorta. Lipids in Health and Disease, 2015, 14, 109.	1.2	22
8	N-acetylcysteine prevents endoplasmic reticulum stress elicited in macrophages by serum albumin drawn from chronic kidney disease rats and selectively affects lipid transporters, ABCA-1 and ABCG-1. Atherosclerosis, 2014, 237, 343-352.	0.4	18
9	Advanced Glycation End Products: A Sweet Flavor That Embitters Cardiovascular Disease. International Journal of Molecular Sciences, 2022, 23, 2404.	1.8	13
10	RAGE Mediates Cholesterol Efflux Impairment in Macrophages Caused by Human Advanced Glycated Albumin. International Journal of Molecular Sciences, 2020, 21, 7265.	1.8	11
11	Plasma advanced glycation end products and soluble receptor for advanced glycation end products as indicators of sterol content in human carotid atherosclerotic plaques. Diabetes and Vascular Disease Research, 2022, 19, 147916412210852.	0.9	9
12	Persistent Effect of Advanced Glycated Albumin Driving Inflammation and Disturbances in Cholesterol Efflux in Macrophages. Nutrients, 2021, 13, 3633.	1.7	7
13	Impact of environmental mercury exposure on the blood cells oxidative status of fishermen living around Mundaú lagoon in Maceió – Alagoas (AL), Brazil. Ecotoxicology and Environmental Safety, 2021, 219, 112337.	2.9	6
14	Advanced glycation end products as biomarkers for cardiovascular disease: browning clarifying atherogenesis. Biomarkers in Medicine, 2020, 14, 611-614.	0.6	4
15	Serum albumin modified by carbamoylation impairs macrophage cholesterol efflux in diabetic kidney disease. Journal of Diabetes and Its Complications, 2021, 35, 107969.	1.2	4
16	Cardiovascular Risk in Patients with Chronic Kidney Disease is Associated with Decrease of HDL Levels. International Journal of Clinical Cardiology, 2018, 5, .	0.1	1
17	Adequate glycemic control prevents cholesterol efflux impairment and lipid accumulation in macrophages induced by advanced glycated albumin. Atherosclerosis, 2018, 275, e171.	0.4	0
18	Skin autofluorescence as an indicator of subclinical atherosclerosis in obese adults. Atherosclerosis, 2020, 315, e72-e73.	0.4	0

#	Article	IF	CITATIONS
19	Plasma advanced glycation end products positively correlates to oxysterols levels in carotid atherosclerotic plaques. Atherosclerosis, 2020, 315, e117.	0.4	0